Table 1 Baseline clinical characteristics of study participatns
Rosuva/Eze 2.5/10 mg (n = 39) | Rosuvastatin 5 mg (n = 36) | P value | |
|---|---|---|---|
Age, years | 66.3 ± 11.7 | 63.0 ± 13.0 | 0.210 |
Male gender, n (%) | 24 (62) | 16 (44) | 0.138 |
BMI, kg/m2 | 25.1 ± 3.6 | 26.5 ± 4.5 | 0.143 |
Systolic blood pressure, mmHg | 127.4 ± 14.9 | 126.7 ± 13.8 | 0.849 |
Diastolic blood pressure, mmHg | 72.2 ± 10.8 | 72.9 ± 8.0 | 0.754 |
Waist circumference, cm | 90.5 ± 11.8 | 93.1 ± 11.0 | 0.360 |
MetSyn, (%) | 17 (50) | 18 (58) | 0.515 |
Prevalence CVD, n (%) | 4 (10) | 2 (6) | 0.376 |
Prevalence CI, n (%) | 4 (10) | 4 (11) | 0.598 |
Hypertension, n (%) | 28 (72) | 23 (64) | 0.463 |
Diabetes therapy | |||
Oral hypoglycemic agent, n (%) | 30 (77) | 30 (83) | 0.488 |
sulfonylurea, n (%) | 16 (41) | 19 (53) | 0.143 |
pioglitazone, n (%) | 17 (44) | 15 (42) | 0.866 |
metformin, n (%) | 14 (36) | 15 (42) | 0.608 |
α-glucosidase inhibitor, n (%) | 8 (21) | 3 (12) | 0.136 |
dipeptidyl peptidase-4 inhibitor, n (%) | 3 (8) | 4 (11) | 0.454 |
Aspartate aminotransferase, U/L | 27.2 ± 12.5 | 21.9 ± 5.6 | 0.596 |
Alanine aminotranserase, U/L | 28.2 ± 16.3 | 21.2 ± 9.8 | 0.216 |
Creatine kinase, IU/L | 130 ± 87 | 118 ± 63 | 0.489 |
Creatinine, mg/dL | 0.8 ± 0.3 | 0.7 ± 0.2 | 0.316 |